The analysis included hormone receptor and HER2/neu status to define subtypes: HR+ HER2+, HR+ HER2−, HR− HER2+, and HR− HER2− ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

What Is HER2-Positive Breast Cancer? HER2-positive breast cancer is when breast cancer cells have a protein receptor called human epidermal growth factor receptor 2 (HER2). Normally, this protein ...

近年来，HER2 在其他多种恶性肿瘤如胃癌、结直肠癌、非小细胞肺癌等中也逐渐「显山露水」，临床应用日益广泛。 1982 年，Robert Weinberg 团队从老鼠的神经母细胞瘤分离出一种致癌基因、命名为「neu 基因」。1985 年，Arthur Levinson 团队在人类基因组 DNA 库中找到了 ...

The Lung Cancer Research Foundation (LCRF) is pleased to announce its collaboration with Bayer Pharmaceuticals to fund two ...

Included studies compared survival between Black and White female patients with breast cancer within subtypes defined by hormone receptor and human epidermal growth factor receptor 2 (HER2)/neu (HER2; ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Groups Develop Request for Proposals for Research Grants Focused on Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations NEW YORK, Sept. 5, 2024 /PRNewswire/ -- The Lung Cancer ...

The potential to treat GEA by targeting HER2 was confirmed in 2010 when researchers showed that adding Roche’s Herceptin to chemotherapy extended OS from 11.1 months to 13.8 months.